secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001171843-24-001514
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end
------------------------------------------------------------------------

- Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.
- Cash and cash equivalents $3.4M at Dec 31, 2023; received $5M post-year-end from Agenus convertible note.
- Launched Phase 2 trial of agenT-797 with botensilimab/balstilimab/chemo in 2L gastroesophageal cancers.
- Entered collaboration with Immunoscape to develop TCR-based therapies against novel targets.
- Nature Communications publication showed >70% survival in ARDS patients on mechanical ventilation with agenT-797.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/0001171843-24-001514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/f8k_032124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer